American Board of Physical Medicine and Rehabilitation (ABPMR), with examination development and administration by the American Board of Psychiatry and Neurology (ABPN) · Current ABPN Neuromuscular Medicine Certification Content Specifications, dated December 1, 2025, linked from the official initial-certification page for the October 19–23, 2026 examination. The document does not state a separate effective date. Verified on October 9, 2026. The workbook label identifies the ABPMR certification pathway to this shared examination; the assigned slug is preserved.

This original 20-question sample covers selected topics across the outline. It does not reproduce official exam questions or cover every tested topic.

• ABPMR — Neuromuscular Medicine
• ABPN — Neuromuscular Medicine
• Neuromuscular Medicine Certification Content Specifications
• Supplementary tables including criteria for diagnosing ALS
• GeneReviews — Spinal Muscular Atrophy
• Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial
• NICE NG42 — Motor neurone disease: assessment and management
• AANEM — Cervical Radiculopathy/Brachial Plexopathy
• A standardized ultrasound approach in neuralgic amyotrophy
• GeneReviews — Hereditary Neuropathy with Liability to Pressure Palsies
• Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies
• Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders
• EAN/PNS guideline on diagnosis and treatment of CIDP — Second revision
• EFNS/PNS guideline on skin biopsy in the diagnosis of small fiber neuropathy
• International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update
• NLM MeSH — Lambert-Eaton Myasthenic Syndrome
• CDC — Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021
• GeneReviews — Myotonic Dystrophy Type 1
• Inclusion body myositis: Update on the diagnostic and therapeutic landscape
• GeneReviews — Pompe Disease
• GeneReviews — Glycogen Storage Disease Type V
• Autoantibodies against HMG-CoA reductase in patients with statin-associated autoimmune myopathy
• Isaacs syndrome: A review
• EAN/PNS Guideline on diagnosis and treatment of Guillain–Barré syndrome
• NIOSH — Performing Motor and Sensory Neuronal Conduction Studies in Adult Humans
• Neuromuscular_Medicine_CERT_Format_and_Scoring.pdf
• Recommendations | Motor neurone disease: assessment and management | Guidance | NICE
• JCI - Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy
• Statins: very infrequent reports of myasthenia gravis - GOV.UK
• 5-EAN-guideline-amyotrophic-lateral-sclerosis-2024.pdf
• International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update - PMC
• International consensus guidance for management of myasthenia gravis: Executive summary - PMC
• zivkovic-et-al-2020-muscle-nerve.pdf